Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

InspireMD Yönetim

Yönetim kriter kontrolleri 1/4

InspireMD's CEO'su Marvin Slosman, Jan2020 tarihinde atandı, in görev süresi 4.75 yıldır. in toplam yıllık tazminatı $ 3.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.6% maaş ve 85.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.025% ine doğrudan sahiptir ve bu hisseler $ 17.13K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 8.1 yıldır.

Anahtar bilgiler

Marvin Slosman

İcra Kurulu Başkanı

US$3.2m

Toplam tazminat

CEO maaş yüzdesi	14.6%
CEO görev süresi	4.8yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	8.1yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Jan 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Feb 11

CEO Tazminat Analizi

Marvin Slosman'un ücretlendirmesi InspireMD'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$3m	US$470k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$697k	US$433k	-US$18m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$410k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$367k	-US$11m

Tazminat ve Piyasa: Marvin 'nin toplam tazminatı ($USD 3.22M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Marvin şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Marvin Slosman (60 yo)

4.8yrs

Görev süresi

US$3,219,321

Tazminat

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 16.9k
Craig Shore	CFO, Chief Administrative Officer	less than a year	US$1.80m	9.33% $ 6.3m
Shane Gleason	Chief Commercial Officer	1.2yrs	US$1.15m	2.11% $ 1.4m
Andrea Tommasoli	Chief Operating Officer	1.6yrs	US$359.27k	1.97% $ 1.3m
Amir Kohen	Senior Vice President of Finance & HR	less than a year	Veri yok	Veri yok
Patrick Verta	Executive Vice President of Clinical & Medical Affairs	less than a year	Veri yok	0.72% $ 492.0k
Pete Ligotti	Executive VP & GM of North America	less than a year	Veri yok	Veri yok
Sol Barer	Special Advisor to the Board	no data	US$13.92k	Veri yok

1.1yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: NSPR 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 16.9k
Michael Berman	Independent Director	11.7yrs	US$380.25k	1.62% $ 1.1m
Elazer Edelman	Member of Advisory Board	no data	Veri yok	Veri yok
Thomas Kester	Independent Director	8.1yrs	US$385.25k	1.27% $ 862.4k
Antonio Colombo	Member of Advisory Board	no data	Veri yok	Veri yok
Alexandre Abizaid	Member of Advisory Board	no data	Veri yok	Veri yok
Martin B. Leon	Member of Advisory Board	no data	Veri yok	Veri yok
Eberhart Grube	Member of Advisory Board	no data	Veri yok	Veri yok
Paul Stuka	Independent Chairman of the Board	13.2yrs	US$574.93k	1.21% $ 822.5k
Kenneth Rosenfield	Chair of Scientific Advisory Board	3.5yrs	Veri yok	Veri yok
Yaron Almagor	Member of Advisory Board	no data	Veri yok	Veri yok
Edo Kaluski	Member of Advisory Board	no data	Veri yok	Veri yok

8.1yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NSPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).

InspireMD Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director exercised options to buy US$153k worth of stock.

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Insider recently bought US$127k worth of stock

InspireMD, Inc. Announces Management Appointments

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

Recent updates

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director exercised options to buy US$153k worth of stock.

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Insider recently bought US$127k worth of stock

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

Consensus estimates of losses per share improve by 46%

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus revenue estimates decrease by 37%, EPS upgraded

Price target decreased to US$5.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought US$68k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$9.00

Full year 2021 earnings: EPS misses analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Insider recently bought US$50k worth of stock

Insider recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

InspireMD: Revolutionizing The Field Of Vascular Stenting

Insider recently bought US$93k worth of stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Earnings beat expectations, revenue disappoints

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: US$0.82

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: US$0.71

New 90-day high: US$0.44

Analysts update estimates

Third quarter 2020 earnings released: US$0.064 loss per share

Revenue beats expectations, earnings disappoint

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing